JAMA Netw Open
Integrase inhibitors in pregnancy show no major neurodevelopmental risk for infants
A U.S. cohort study of 1,006 HIV-exposed but uninfected infants found no clinically meaningful differences in cognitive, language, or motor scores at 1 year between those exposed in utero to INSTI-based antiretroviral regimens and those exposed to protease inhibitor–based regimens. Scores were near population norms, though infants exposed to INSTIs scored slightly lower than those exposed to NNRTI-based regimens.
Clinical takeaway: Findings support current recommendations for INSTI-based regimens as first-line treatment in pregnant women with HIV, though ongoing surveillance of long-term outcomes remains important.
Source:
Williams PL, et al. (2025, November 3). JAMA Netw Open. Maternal Use of Integrase Strand Transfer Inhibitors During Pregnancy and Infant Neurodevelopment. https://pubmed.ncbi.nlm.nih.gov/41296482/